Stryker Corp. (NYSE:SYK) shares saw an uptick in trading volume on Monday . 1,660,422 shares changed hands during mid-day trading, an increase of 74% from the previous session’s volume of 954,649 shares.The stock last traded at $116.28 and had previously closed at $114.44.

A number of brokerages have issued reports on SYK. Brean Capital reissued a “buy” rating and issued a $125.00 price target (up from $121.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Jefferies Group reissued a “hold” rating and issued a $120.00 price target (up from $113.00) on shares of Stryker Corp. in a research note on Monday, July 25th. Canaccord Genuity reissued a “buy” rating and issued a $130.00 price target on shares of Stryker Corp. in a research note on Sunday, July 24th. Needham & Company LLC reissued a “hold” rating on shares of Stryker Corp. in a research note on Sunday, July 24th. Finally, JPMorgan Chase & Co. reissued a “hold” rating and issued a $119.00 price target on shares of Stryker Corp. in a research note on Friday, July 22nd. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. Stryker Corp. currently has an average rating of “Hold” and a consensus target price of $114.91.

The company has a market capitalization of $43.52 billion and a price-to-earnings ratio of 27.41. The stock’s 50-day moving average price is $116.78 and its 200-day moving average price is $111.22.

Stryker Corp. (NYSE:SYK) last released its quarterly earnings results on Thursday, July 21st. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.02. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.79 billion. Equities research analysts forecast that Stryker Corp. will post $5.76 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Stockholders of record on Friday, September 30th will be paid a dividend of $0.38 per share. The ex-dividend date of this dividend is Wednesday, September 28th. This represents a $1.52 annualized dividend and a dividend yield of 1.31%.

In other news, Director Howard E. Cox, Jr. sold 9,448 shares of the company’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $117.02, for a total transaction of $1,105,604.96. Following the completion of the sale, the director now owns 554,732 shares in the company, valued at approximately $64,914,738.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Srikant Datar sold 6,565 shares of the company’s stock in a transaction dated Monday, June 6th. The stock was sold at an average price of $113.90, for a total value of $747,753.50. Following the sale, the director now owns 16,642 shares of the company’s stock, valued at approximately $1,895,523.80. The disclosure for this sale can be found here.

Several institutional investors have bought and sold shares of SYK. KBC Group NV boosted its position in Stryker Corp. by 2.2% in the fourth quarter. KBC Group NV now owns 38,334 shares of the medical technology company’s stock valued at $3,563,000 after buying an additional 818 shares in the last quarter. American International Group Inc. boosted its position in Stryker Corp. by 3.2% in the fourth quarter. American International Group Inc. now owns 126,422 shares of the medical technology company’s stock valued at $11,749,000 after buying an additional 3,977 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Stryker Corp. by 3.5% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 855,885 shares of the medical technology company’s stock valued at $79,546,000 after buying an additional 29,304 shares in the last quarter.

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.